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Type 2 diabetic patients are characterized by a decreased fat oxidative capacity and high levels of circulating free fatty acids (FFAs). The latter
is known to cause insulin resistance, in particularly in skeletal muscle, by reducing insulin stimulated glucose uptake, most likely via accumulation
of lipid inside the muscle cell. A reduced skeletal muscle oxidative capacity can exaggerate this. Furthermore, type 2 diabetes is associated with
impaired metabolic flexibility, i.e. an impaired switching from fatty acid to glucose oxidation in response to insulin. Thus, a reduced fat oxidative
capacity and metabolic inflexibility are important components of skeletal muscle insulin resistance. The cause of these derangements in skeletal
muscle of type 2 diabetic patients remains to be elucidated. An impaired mitochondrial function is a likely candidate. Evidence from both in vivo
and ex vivo studies supports the idea that an impaired skeletal muscle mitochondrial function is related to the development of insulin resistance
and type 2 diabetes mellitus. A decreased mitochondrial oxidative capacity in skeletal muscle was revealed in diabetic patients, using in vivo 31-
Phosphorus Magnetic Resonance Spectroscopy (31P-MRS). However, quantification of mitochondrial function using ex vivo high-resolution
respirometry revealed opposite results. Future (human) studies should challenge this concept of impaired mitochondrial function underlying
metabolic defects and prove if mitochondria are truly functional impaired in insulin resistance, or low in number, and whether it represents the
primary starting point of pathogenesis of insulin resistance, or is just an other feature of the insulin resistant state.
© 2008 Elsevier Inc. All rights reserved.Keywords: Type 2 diabetes; Insulin resistance; Muscle metabolic function; Mitochondrial function1. Introduction
The incidence of type 2 diabetes mellitus is rapidly in-
creasing and is reaching endemic proportions. It is estimated
that currently worldwide 190 million people suffer from dia-
betes, with a predicted increase to 300 million in 2025 [1,2].
Two key features in the pathogenesis of type 2 diabetes mellitus
are a decreased ability of insulin to perform its normal phy-
siological role, insulin resistance [3], and the inability of the
pancreatic β-cell to adequately secrete insulin, β-cell failure [4].
It is well recognized that fatty acid metabolism plays an
important role in the development of insulin resistance and type⁎ Corresponding author. Nutrition and Toxicology Research Institute
Maastricht (NUTRIM), Department of Human Biology, Maastricht University,
P.O. Box 616, 6200 MD Maastricht. Tel.: +31 43 3884258; fax: +31 43
3670976.
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doi:10.1016/j.physbeh.2008.01.0202 diabetes mellitus [5]. Evidence is now accumulating that
ectopic lipid accumulation –i.e. lipid deposition in non-adipose
tissue – is a central feature of the disease. Recently the role of
mitochondria has gained interest in explaining the disturbed
fatty acid metabolism and insulin resistance in type 2 diabetes,
especially in skeletal muscle. In this review, we will discuss the
metabolic defects in type 2 diabetes mellitus and address the
role of skeletal muscle mitochondrial function.
2. Insulin resistance
The two most important organs affected by insulin resistance
are liver and skeletal muscle. Type 2 diabetes is characterized by
an increased postabsorptive (‘basal’) hepatic glucose production
(HGP) and a reduced ability of insulin to suppress HGP (hepatic
insulin resistance), which contributes to hyperglycemia [6]. In
healthy individuals, an increased gluconeogenesis is compen-
sated by a decreased glycogenolysis, due to concomitant hy-
perinsulinemia, thereby maintaining hepatic glucose output at
Fig. 1. Metabolic inflexibility. Healthy subjects (solid line) display metabolic
flexibility, i.e. heavily rely on lipid as source for substrate oxidation during
fasting (low respiratory quotient, RQ) and rapidly switch to glucose oxidation
upon insulin-stimulation (high RQ). In contrast, insulin-resistant – metabolic
inflexible – subjects display a lower rate of lipid oxidation under fasting
conditions (increased RQ), and do hardly increase glucose oxidation upon
insulin-stimulation (lower RQ) compared to healthy individuals. (adapted from
Kelley and Mandarino [32]).
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2 diabetes, a breakdown of this hepatic autoregulation is
suggested to underlie the increased hepatic glucose output [9].
Increased circulating plasma free fatty acids (FFA) are impli-
cated in these defects in hepatic glucose metabolism (for review
see [10]).
Skeletal muscle is responsible for the major part (N80%) of
insulin-stimulated whole body glucose disposal, and hence plays
an important role in the pathogenesis of insulin resistance. There is
ample evidence showing that an acute increase in plasma FFA, via
intravenous lipid infusion, can induce skeletal muscle insulin
resistance in non-diabetic and diabetic subjects (see for review
[11]), while an acute lowering of elevated plasma FFA levels
lowered insulin resistance in obese diabetic and non-diabetic
subjects [12]. Several mechanisms have been proposed to explain
the mechanism responsible for these FFA-induced defects. The
glucose fatty-acid cycle as postulated by Randle, coupled an
increased lipid availability and fat oxidation to a decreased glucose
uptake and oxidation [5]. Although the Randle cycle is a valid
physiological principle, many observations now argue against a
role for the glucose fatty-acid cycle in explaining fatty acid-
induced insulin resistance in skeletal muscle [13–16], and suggest
that FFA primarily inhibit glucose transport and not glycolysis.
An increased accumulation of triacylglycerol within skeletal
muscle (intramyocellular lipid, IMCL) is closely related to the
degree of insulin resistance [17–19]. Evidence, however, is ac-
cumulating that not IMCL itself causes insulin resistance, but
rather some other lipid metabolites associated with intramuscular
triacylglycerol, i.e. long-chain fatty acyl-CoA (LCFA-CoA), dia-
cylglycerol (DAG) and/or ceramide [20–23]. Thus, accumulation
of lipid (metabolites) within the muscle could induce insulin
resistance, through direct effects on glucose utilization by altering
enzyme activities or through interference with insulin signaling.
However, what causes lipid accumulation?
3. Fat oxidative capacity and metabolic flexibility
Type 2 diabetic subjects are characterized by a decreased
capacity to oxidize fat [24–28]. Sampling skeletal muscle tissue,
a diminished oxidative capacity was revealed [24,29,30]. The
metabolic capacity of insulin resistant skeletal muscle appears to
be organized towards fat esterification rather than fat oxidation
[29]. A dysbalance between fatty acid uptake and fatty acid
oxidation could easily lead to fat accumulation within skeletal
muscle, which can, as discussed earlier, induce insulin resis-
tance. Interestingly, we demonstrated that male subjects with
milder forms of hyperglycemia (i.e. impaired glucose tolerance,
IGT) have the same defects in fatty acid utilization as subjects
with type 2 diabetes mellitus [31], suggesting that these dis-
turbances may play an important role in the development of IGT
and type 2 diabetes mellitus.
Next to an impaired fasting fat oxidation, skeletal muscle of
insulin resistant subjects is characterized by so-called ‘meta-
bolic inflexibility’ [32]. Thus, healthy lean individuals rely on
fat oxidation under fasting conditions and switch easily to
carbohydrate oxidation in response to insulin stimulation. This
flexibility, however, is lost in the insulin resistant (diabetic) state(see Fig. 1). Metabolic flexibility is positively correlated with
insulin sensitivity [33], and anti-diabetic treatment with thia-
zolidinediones [34], or a program of weight-loss and improved
aerobic fitness training [35], is able to improve metabolic flex-
ibility. A state of metabolic inflexibility could contribute to the
accumulation of IMCL, and thus contribute to the development
of insulin resistance and type 2 diabetes. However, it could also
be a reflection of the insulin resistant state, with both carbo-
hydrate and fat oxidation being less sensitive to the normal
physiological response of insulin.
To test the hypothesis that metabolic switching is an intrinsic
characteristic of skeletal muscle, Ukropcova et al [33] performed
series of in vitro experiments in myotubes grown from healthy
human volunteers, in which dynamic changes of fat oxidation
were evaluated. The capacity of glucose to suppress fat oxidation
(‘suppressibility’), and palmitate to increase fat oxidation (‘adapt-
ability’) was measured and correlated to in vivo insulin sensitivity
and metabolic flexibility. Suppressibility was inversely correlated
with insulin sensitivity andmetabolic flexibility, while adaptability
was positively correlated with both metabolic characteristics [33].
From this, it was concluded that metabolic switching is an intrinsic
property of skeletal muscle. This leaves the question what cellular
defects can underlie the metabolic inflexibility and the reduced fat
oxidative capacity seen in skeletal muscle of insulin resistant
subjects. In a recent paper it was revealed that metabolic in-
flexibility and reduced mitochondrial mass clustered together in
subjects with a family history of diabetes [36], supporting the role
of intrinsic skeletal muscle metabolic defect in the pathogenesis of
insulin resistance and diabetes, and suggesting that proper mito-
chondrial function seems crucial.
4. Impaired skeletal muscle mitochondrial function and
type 2 diabetes
In search for the cellular causes of the metabolic disturbances
seen in skeletal muscle of insulin resistant subjects, mitochondria
Fig. 2. Measuring in vivo mitochondrial function with 31P-MRS using an
exercise protocol. (A) Typical, 31P-MR spectrum of the vastus lateralis muscle at
rest. The arrows point out inorganic phosphate (Pi), phosphodiester (PDE),
creatine phosphate (PCr), and adenosinetriphosphate (ATP). (B) PCr recovery of
an individual patient with the mono- exponential growth preceded by the steady
state fitted to the measured data (t1/2=24.9 seconds) [37].
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They provide the energy for almost all cellular processes and are
themain oxygen consumer of the body. Proper oxidative substrate
utilization and fuel switching require proper mitochondrial
function. During the last few years the role of mitochondria in
the pathogenesis of insulin resistance and type 2 diabetes has
gained interest.
In vivo studies, using non-invasive 31-Phosporus Magnetic
Resonance Spectroscopy (31P-MRS), point towards an impaired
mitochondrial function in type 2 diabetic patients [37,38], first-
degree relatives of type 2 diabetic patients [39], and in elderly
[40]. Petersen et al [39] were the first to examine in vivo
mitochondrial function in lean, insulin-resistant offspring of
patients with type 2 diabetes. Mitochondrial oxidative phos-
phorylation activity was determined by analyzing saturation
transfer between inorganic phosphate and ATP in the resting
soleus muscle. A reduced mitochondrial oxidative phosphor-
ylation was found in insulin resistant offspring compared to
insulin-sensitive controls, and was associated with an increased
IMCL content [39]. Interestingly, they recently revealed that - in
a comparable group of insulin-resistant offspring - a reduced
mitochondrial density may be involved in decreased mitochon-
drial function [41].
Similar defects in mitochondrial function as seen in the
offspring were found in lean, elderly insulin-resistant subjects
[40]. However, in contrast to insulin resistant offspring of type 2
diabetic patients, it is likely that in elderly people an acquired
defect in mitochondrial activity, rather than inherited defect,
may lead to the decrement in skeletal muscle mitochondrial
function. Also using the saturation transfer method, Szendroedi
et al [38] observed that diabetic patients had a lower fasting ATP
synthetic flux compared to young controls, but not compared
to sex-, age-, and body mass index (BMI)-matched controls.
However, increased fasting FFA and insulin resistance already
characterized these matched control compared to young con-
trols. Insulin stimulation increased ATP synthetic flux in both
groups of controls but failed to increase in patients with T2DM.
The authors concluded that lipid availability primarily deter-
mines fasting ATP flux, whereas insulin sensitivity defines
insulin-stimulated ATP flux [38].
We determined in vivo mitochondrial function in the vastus
lateralis muscle of type 2 diabetic patients and age and BMI-
matched normoglycemic control subjects, employing an alter-
native 31P-MRS method, i.e. measuring the phosphate creatine
(PCr) kinetics during recovery from exercise [42]. During
exercise, PCr content decreases transiently and recovers rapidly
after exercise. In the post-exercise state PCr resynthesis is
driven purely oxidatively [43] and the resynthesis rate reflects
mitochondrial capacity. An advantage of this method is that
mitochondrial function can be assessed under conditions of
increased metabolic demand. In short, after a magnetic re-
sonance image is acquired from the upper leg, a non-saturated
spectrum is acquired. In this spectrum (see Fig. 2A for a typical
example), several peaks can be fitted. Subsequently, a series of
spectra is acquired during 2 minutes of rest, 5 minutes of knee-
extension exercise and 5 minutes of recovery. Finally, the time-
course of the PCr amplitude (PCr(t)) during the last 20 secondsof exercise (steady state) and during the recovery period is
fitted. From the fitted curve, the T1/2 of the PCr recovery half-
time is determined (see Fig. 2B), which reflects skeletal muscle
mitochondrial oxidative capacity. Using this approach, a 45%
prolonged PCr half-time was found in type 2 diabetic patients
compared to control subjects [37]. PCr half-time correlated
positively with plasma glucose concentration in the diabetic
population, revealing that the decrease in oxidative capacity is
related to the degree of the disease. Interestingly, IMCL content
was not different between type 2 diabetic patients and BMI-
matched control subjects [37]. Furthermore, we found a cor-
relation between PCr half-time and whole-body maximal oxy-
gen consumption (VO2-max). It is known for long time that
VO2-max is reduced in diabetic subjects [44]. Our data indicate
that VO2max is a good reflection of skeletal muscle mito-
chondrial oxidative capacity.
Taken together, in vivo data support the hypothesis that an
impaired mitochondrial oxidative capacity – or function – is an
early factor in the pathogenesis of type 2 diabetes. Although
oxygen consumption takes place at the level of themitochondria,
cardiac output, oxygen transport through the circulation, skeletal
255E. Phielix, M. Mensink / Physiology & Behavior 94 (2008) 252–258muscle capillary density and perfusion, as well as a reduced
mitochondrial content and a real intrinsic mitochondrial dys-
function (i.e. lower respiratory capacity per mitochondrion)
can all affect skeletal muscle mitochondrial oxidative capacity.
The question remains whether a true mitochondrial dysfunction
underlies the impaired skeletal muscle metabolic function seen
in first-degree relatives and diabetic patients, and whether this is
explained by a reduced mitochondrial density or functional
impaired mitochondria.
4.1. Intrinsic mitochondrial aberrations in type 2 diabetes?
The group of Kelley was the first to report an impaired
activity of marker enzymes of oxidative pathways in skeletal
muscle from individuals with obesity and type 2 diabetes [45].
These findings raised the possibility of true impaired mitochon-
drial function involved in the pathogenesis of insulin resistance.
They also showed lowered activity of NADH:O2 oxidoreduc-
tase, reflecting over-all activity of the electron transport chain
(ETC), and of citrate synthase, indicative of mitochondria
content, in type 2 diabetic patients compared to obese and lean
control subjects [46]. These findings suggested that an impaired
functional capacity of mitochondria might contribute to the
disturbances in substrate metabolism as seen in muscle of dia-
betic patients. In the same study, size andmorphology of skeletal
muscle mitochondria were assessed using electron microscopy
[46]. It was revealed that mitochondria were smaller in obese and
type 2 diabetic subjects compared to lean controls, with the
mitochondrial longitudinal area positively correlating with in-
sulin sensitivity. Furthermore, only inmuscle of obese and type 2
diabetic individuals enlarged fractured mitochondria were found
[46]. In a more recent study [47] it was reported that mito-
chondrial function was especially impaired in the subsarcolem-
mal fraction of mitochondria, and, interestingly, mitochondrial
function was still significantly decreased after normalization for
mitochondrial content in obese and type 2 diabetic individuals,
indicating a true functional impairment.
To further examine if mitochondrial aberrations were due to
intrinsic defects or a reduction in mitochondrial content, a few
studies were performed in which mitochondrial function was
normalized for mitochondrial content, using citrate synthase
activity or mitochondrial copy DNA number (mtDNA). After
normalization, some studies indeed revealed a functional im-
pairment inmitochondria of type 2 diabetic patients [47,48], while
other studies found no differences [46,49]. Citrate synthase ac-
tivity is often used as a marker for mitochondrial content, the
activity of this enzyme, however, reflects both mitochondrial
mass and mitochondrial enzyme activity. Furthermore, reduced
activity of oxidative enzymes does not necessarily reflect mito-
chondrial function, because only part of the mitochondrial oxi-
dative system is studied. Moreover, this is done out of its
functional context, i.e. activity of single complexes of the ETC are
often measured independent of the control of the oxidative
phosphorylation system that is present in functional mitochon-
dria. Therefore, true functionalmitochondrial impairments should
be studied using polarografic respiratory measurements in iso-
lated mitochondria or permeabilized muscle fibers.Two recent studies explored enzyme capacities of the ETC
using respirometry measurements [48,49]. Oxygen consump-
tion of intact mitochondria can be determined in presence of
substrates or inhibitors of the ETC complexes. In this way,
oxygen consumption coupled to substrate oxidation and energy
production can be evaluated. When uncoupling agents of the
ETC are added, the proton gradient over the inner mitochondrial
membrane is lost and oxygen consumption is maximized to
compensate for this loss of gradient. In this way, maximal ETC
enzyme capacity can be measured.
Using such an approach, a decreased mitochondrial function,
was seen in type 2 diabetic patients compared to control subjects
[48], as measured in isolated mitochondria. These data provided
evidence for a functional impairment in mitochondrial respiration
related to type 2 diabetes. However, another study observed a
lower ADP-stimulated state 3 respiration and a lower uncoupled
respiration in permeabilized muscle fibers from type 2 diabetic
patients [49]. After normalization for citrate synthase differ-
ences were no longer found compared tomatched control subjects
[49]. From this data it was concluded that mitochondrial function
is normal in type 2 diabetes and that the observed blunted coupled
and uncoupled respiration can be attributed to lower mitochon-
drial content. A reason for the discrepancy in the results of both ex
vivo studies may be the different methods used to assess mito-
chondrial oxygen consumption, i.e. isolated mitochondria vs
permeabilized fibers. Isolatedmitochondria loose their interaction
with the cytoplasm in contrast to permeabilized muscle fibers, in
which the mitochondria are kept in their native environment. In
addition, permeabilized muscle fibers have some endogenous
substrates left, in contrast to isolatedmitochondria, which can also
influence the outcome in mitochondrial function.
More research is needed to investigate whether the impaired
mitochondrial oxidative phosphorylation and ETC capacity in
type 2 diabetes can fully accounted for by a diminished mito-
chondrial content, or reflects (also) a functional impairment in
mitochondria.
4.2. PGC-1α and mitochondrial function
Which factors – inherited or acquired – could be responsible
for the reduced mitochondrial function in insulin resistant
skeletal muscle? The peroxisome proliferator-activated recep-
tor-γ coactivator 1α (PGC-1α) is a likely candidate. PGC-1α
supports the transcriptional activity of nuclear respiratory fac-
tors (NRFs), which regulate the transcription of genes involved
in oxidative metabolism (OXPHOS), and stimulate mtTFA, a
key transcriptional factor for the mitochondrial genome. There-
fore, as a result of a reduced level of PGC-1α in insulin resistant
states, a reduction in mitochondrial function can be anticipated.
Indeed, two DNAmicroarray studies [50,51] revealed a lowered
expression of a set of genes involved in oxidative phosphoryla-
tion under control of PGC-1α, as well as PGC-1α itself, in
skeletal muscle of type 2 diabetic patients [50,51] and offspring
of type 2 diabetic parents [50]. The association between PGC-
1α and diabetes is further established by studies revealing an
association between polymorphisms PGC-1α and an increased
risk on diabetes [52,53].
Fig. 3. Proposed series of events explaining skeletal muscle insulin resistance.
Both, environmental factors (e.g. physical activity, dietary intake, aging) and
genetic factors (e.g. polymorphisms) reduce the expression of genes, controlled
of PGC-1a, involved in oxidative metabolism and mitochondrial biogenesis.
This will impair mitochondrial function, either due to a reduced mitochondrial
density or functional mitochondrial impairment, or both. As a consequence
subtle changes in skeletal muscle metabolic function become manifest, i.e. a
reduced fasting lipid oxidation rate and metabolic inflexibility. These
derangements will contribute, together with an increased delivery of FFA, to
an accumulation of lipid inside the muscle cell. Lipid metabolites associated
with IMCL, like diacylglycerol (DAG) and fatty acyl-CoA, can activate (certain)
PKC isoforms inducing insulin-resistance, through interference with insulin
signaling. The reduced insulin-stimulated skeletal muscle glucose disposal,
in concert with an increased hepatic glucose output and failure of the pancreatic
β-cell, contributes to the development of clinically overt type 2 diabetes
mellitus. Features of the insulin resistant state, like hyperglyceamia, hyper-
insulinaemia and IMCL accumulation can further deteriorate skeletal muscle
mitochondrial function, creating a vicious cycle.
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approximately 60% reduction in PGC-1α mRNA level in
skeletal muscle of type 2 diabetic patients compared with BMI
and age-matched controls [34]. In addition, PGC-1α expression
restored after treatment with the anti-diabetic agent Rosiglita-
zone together with an improvement in muscular insulin sen-
sitivity, and an improved metabolic function [34]. In contrast,
Morino et al [41] found no differences in PGC-1α expression or
in the expression of transcription factors controlled by PGC-1α
(e.g. NRFs, mtTFA) between insulin resistant offspring of type
2 diabetic parents and BMI and age-matched control subjects,
although mitochondrial content was decreased in offspring.
Multiple genetic and environmental factors (e.g. physical acti-
vity, age) can influence the expression of PGC-1α [54]. This
could have influenced the results, as Morino et al [41] measured
young, lean subjects, in contrast to the middle-aged, overweight
participants measured in studies showing a reduced PGC-1α
expression [34,50,51]. However, it cannot be excluded that
other mechanisms than regulation by PGC-1α are responsible
for the reduced mitochondrial content in lean, insulin resistant
offspring.
4.3. Mitochondrial dysfunction: cause or consequence?
Many studies point towards a reduced mitochondrial oxi-
dative capacity –or function- as an important feature of type 2
diabetes mellitus. A series of events can be proposed to explain
mitochondrial dysfunction and the increased insulin resistance
observed in skeletal muscle of patients with type 2 diabetes
mellitus (see Fig. 3). The reduced mitochondrial function ob-
served in young, lean offspring of type 2 diabetic patients [39],
makes it likely to be an early event, and therefore a potential
primary cause of type 2 diabetes mellitus, as offspring of type 2
diabetic patients are at increased risk to develop the disease.
However, although not hyperglycemic, offspring of type 2 dia-
betic patients are already characterized by many of the metabolic
derangements seen in type 2 diabetes: insulin resistance [39],
hyperinsulinaemia [39], metabolic inflexibility [36], increased
skeletal muscle lipid accumulation [19,39] and – sometimes -
increased circulating FFA levels [19]. This makes it still possible
that the reduced mitochondrial function as seen in offspring is
consequence of the (pre)diabetic insulin-resistant state rather
than cause. Moreover, Asmann et al [55] compared mtDNA copy
number, indicative of mitochondrial content, and skeletal muscle
ATP production between type 2 diabetic patients and non-diabetic
controls at similar postabsorptive plasma insulin and glucose
concentrations and observed no difference. They concluded that
the difference in mitochondrial function between type 2 diabetic
patients and nondiabetic subject is attributable to multiple fac-
tors related to insulin action rather than an intrinsic metabolic
defect [55]. Furthermore, it is suggested that increased lipid
accumulation in muscle cells could impair mitochondrial oxi-
dative capacity due to lipid peroxidation-induced damage to
mitochondria [56]. This would further exacerbate intramyocel-
lular lipid accumulation. In support of this idea, skeletal muscle
of obese insulin resistant subjects, not only contains more lipid,
but these lipids did show a higher degree of peroxidation [57].However, whether this indeed can affect mitochondrial function
needs to be proven.
5. Conclusion
Reviewing the existing data, evidence from both in vivo and
ex vivo studies supports the idea that an impaired skeletal
muscle mitochondrial function is related to the development of
insulin resistance and type 2 diabetes mellitus. Future (human)
studies should challenge this concept of impaired mitochondrial
function and prove if mitochondria are truly functional impaired
in insulin resistance, or low in number, and whether it represents
the primary starting point of pathogenesis of insulin resistance,
or is just an other feature of the insulin resistant state.
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